Glioma

At the American Society of Clinical Oncology (ASCO) annual meeting, researchers reported on a…

Newark, New Castle, USA, June 23, 2023 (GLOBE NEWSWIRE) -- The market analysis of the global adult malignant glioma therapeutics market was conducted by Growth Plus Reports in 2022 and…

ERAS-801 has now received ODD in addition to FDA Fast Track Designation Initial THUNDERBBOLT-1 Phase 1 monotherapy data in patients with recurrent GBM expected in H2 2023 SAN DIEGO, June…

Wilmington, Delaware, United States, June 09, 2023 (GLOBE NEWSWIRE) -- The global glioma treatment market size stood at US$ 4.39 Bn in 2021 and is likely to exceed US$ 7.51 Bn by 2031,…

In an international study co-led by UCLA, scientists have shown that a new targeted therapy drug can extend the amount of time people with a subtype of glioma are on treatment without their…

CHICAGO -- Oral vorasidenib monotherapy significantly improved progression-free survival (PFS), and delayed the…

Overall response rate (ORR) of 67% and clinical benefit rate (CBR) of 93% in 69 heavily pretreated RANO-HGG evaluable patients The Company expects to complete rolling NDA submission in…

Phoenix, AZ, June 02, 2023 (GLOBE NEWSWIRE) -- The Ivy Brain Tumor Center at Barrow Neurological Institute, the nation’s largest early-phase drug development program dedicated to brain…

<!-- Name:DistributionId Value:8846053 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False -->…

<!-- Name:DistributionId Value:8841403 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False -->…